TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors

References

• Khan Y , Lyou Y , El-Masry M , et al. Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13(1):31–38.
   PubMed Web of Science ®Google Scholar
• Fürstenau M , Hallek M , Eichhorst B. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019;104(11):2144–2154.
   PubMed Web of Science ®Google Scholar
• Döhner H , Stilgenbauer S , Benner A , et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S , Schnaiter A , Paschka P , et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–3254.
   PubMed Web of Science ®Google Scholar
• Zaja F , Mian M , Volpetti S , et al. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. Am J Hematol. 2013;88(11):955–960.
   PubMed Web of Science ®Google Scholar
• Gaidano G , Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology Am Soc Hematol Educ Program. 2017;2017(1):329–337.
   PubMedGoogle Scholar
• Rossi D , Terzi-di-Bergamo L , De Paoli L , et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921–1924.
   PubMed Web of Science ®Google Scholar
• Thompson PA , Tam CS , O’Brien SM , et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309.
   PubMed Web of Science ®Google Scholar
• Fischer K , Bahlo J , Fink AM , et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–215.
   PubMed Web of Science ®Google Scholar
• Chai-Adisaksopha C , Brown JR . FCR achieves long-term durable remissions in patients with IGHV-mutated CLL. Blood. 2017;130(21):2278–2282.
   PubMed Web of Science ®Google Scholar
• Gentile M , Shanafelt TD , Reda G , et al. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia. 2018;32(8):1869–1873.
   PubMed Web of Science ®Google Scholar
• Herling CD , Coombes KR , Benner A , et al. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol. 2019;20(11):1576–1586.
   PubMed Web of Science ®Google Scholar
• Molica S , Giannarelli D , Montserrat E . Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(7):423–430.
   PubMed Web of Science ®Google Scholar
• Thompson PA , Srivastava J , Peterson C , et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019;134(22):1951–1959.
   PubMed Web of Science ®Google Scholar
• International CLL-IPI working group . An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790.
   PubMed Web of Science ®Google Scholar
• Gentile M , Shanafelt TD , Mauro FR , et al. Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. Eur J Haematol. 2018;101(5):703–706.
   Web of Science ®Google Scholar
• Muñoz-Novas C , Poza-Santaella M , González-Gascón Y Marín I , et al. The international prognostic index for patients with chronic lymphocytic leukemia has the higher value in predicting overall outcome compared with the barcelona-brno biomarkers only prognostic model and the MD anderson cancer center prognostic index. Biomed Res Int. 2018;2018:9506979.
   PubMed Web of Science ®Google Scholar
• Gentile M , Shanafelt TD , Mauro FR , et al. Comparison between the CLL-IPI and the barcelona-brno prognostic model: analysis of 1299 newly diagnosed cases. Am J Hematol. 2018;93(2):E35–E37.
   PubMed Web of Science ®Google Scholar
• Molica S , Giannarelli D , Mirabelli R , et al. Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis. Ann Hematol. 2018;97(10):2005–2008.
   PubMed Web of Science ®Google Scholar
• Burger JA , Tedeschi A , Barr PM , et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Barr PM , Robak T , Owen C , et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502–1510.
   PubMed Web of Science ®Google Scholar
• Burger JA , Barr PM , Robak T , et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD , Wang XV , Kay NE , et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Woyach JA , Ruppert AS , Heerema NA , et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Moreno C , Greil R , Demirkan F , et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. .
   PubMed Web of Science ®Google Scholar
• Byrd JC , Brown JR , O’Brien S , et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
   PubMed Web of Science ®Google Scholar
• Furman RR , Sharman JP , Coutre SE , et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A , Cramer P , Demirkan F , et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–211.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD , Barrientos JC , Brown JR , et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311.
   PubMed Web of Science ®Google Scholar
• Fornecker L-M , Aurran-Schleinitz T , Michallet A-S , et al. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Am J Hematol. 2015;90(6):511–514.
   PubMed Web of Science ®Google Scholar
• Cuneo A , Follows G , Rigolin GM , et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103(7):1209–1217.
   PubMed Web of Science ®Google Scholar
• Munir T , Brown JR , O’Brien S , et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.
   PubMed Web of Science ®Google Scholar
• Brown JR , Hillmen P , O’Brien S , et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83–91.
   PubMed Web of Science ®Google Scholar
• Jones J , Mato A , Coutre S , et al. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018;182(4):504–512.
   PubMed Web of Science ®Google Scholar
• Robertson LE , Plunkett W , McConnell K , et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10(3):456–459.
   PubMed Web of Science ®Google Scholar
• Cimmino A , Calin GA , Fabbri M , et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–13949.
   PubMed Web of Science ®Google Scholar
• Perini GF , Ribeiro GN , Pinto Neto JV , et al. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol. 2018;11(1):65.
   PubMedGoogle Scholar
• Anderson MA , Deng J , Seymour JF , et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215–3224.
   PubMed Web of Science ®Google Scholar
• Roberts AW , Davids MS , Pagel JM , et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S , Eichhorst B , Schetelig J , et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S , Eichhorst B , Schetelig J , et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–1980. .
   PubMed Web of Science ®Google Scholar
• Souers AJ , Leverson JD , Boghaert ER , et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Seymour JF , Kipps TJ , Eichhorst B , et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Fischer K , Al-Sawaf O , Bahlo J , et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Sherman RE , Anderson SA , Dal Pan GJ , et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297.
   PubMed Web of Science ®Google Scholar
• Salles G , Bachy E , Smolej L , et al. Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. Ann Hematol. 2019;98(12):2749–2760.
   PubMed Web of Science ®Google Scholar
• Ysebaert L , Aurran-Schleinitz T , Dartigeas C , et al. Real-world results of ibrutinib in relapsed/refractory CLL in France: early results on a large series of 428 patients. Am J Hematol. 2017;92(8):E166–E168.
   PubMed Web of Science ®Google Scholar
• Dimou M , Iliakis T , Pardalis V , et al. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leuk Lymphoma. 2019;60(12):2939–2945.
   PubMed Web of Science ®Google Scholar
• Winqvist M , Andersson P-O , Asklid A , et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Haematologica. 2019;104(5):e208–e210.
   PubMed Web of Science ®Google Scholar
• Winqvist M , Asklid A , Andersson PO , et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the swedish chronic lymphocytic leukemia group. Haematologica. 2016;101(12):1573–1580.
   PubMed Web of Science ®Google Scholar
• Gentile M , Morabito F , Del Poeta G , et al. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia. 2020; DOI:10.1038/s41375-020-0833-x.
   Google Scholar
• Soumerai JD , Ni A , Darif M , et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019;6(7):e366–e374.
   PubMed Web of Science ®Google Scholar
• Mato AR , Thompson M , Allan JN , et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511–1517.
   PubMed Web of Science ®Google Scholar
• Byrd JC , Harrington B , O’Brien S , et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–332.
   PubMed Web of Science ®Google Scholar
• Ghia P , Pluta A , Wach M , et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020; JCO1903355.
   PubMed Web of Science ®Google Scholar
• Sharman JP , Egyed M , Jurczak W , et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291.
   PubMed Web of Science ®Google Scholar
• Soussi T . Caron de Fromentel C, May P. Oncogene. 1990;5:945–952.
   PubMed Web of Science ®Google Scholar
• Malkin D , Li FP , Strong LC , et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233–1238.
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER , Lowe SW . Putting p53 in Context. Cell. 2017;170(6):1062–1078.
   PubMed Web of Science ®Google Scholar
• Vousden KH , Lane DP . p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275–283.
   PubMed Web of Science ®Google Scholar
• Menendez D , Inga A , Resnick MA . The expanding universe of p53 targets. Nat Rev Cancer. 2009;9(10):724–737.
   PubMed Web of Science ®Google Scholar
• Leroy B , Fournier JL , Ishioka C , et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013;41(D1):D962–969.
   PubMed Web of Science ®Google Scholar
• Cerami E , Gao J , Dogrusoz U , et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Gao J , Aksoy BA , Dogrusoz U , et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
   PubMed Web of Science ®Google Scholar
• Zenz T for the European Research Initiative on CLL (ERIC) , Vollmer D , Trbusek M , et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia. 2010;24(12):2072–2079.
   PubMed Web of Science ®Google Scholar
• Cho Y , Gorina S , Jeffrey PD , et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265(5170):346–355.
   PubMed Web of Science ®Google Scholar
• Oren M , Rotter V . Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2(2):a001107.
   PubMed Web of Science ®Google Scholar
• Kato S , Han S-Y , Liu W , et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 2003;100(14):8424–8429.
   PubMed Web of Science ®Google Scholar
• Bisio A , Ciribilli Y , Fronza G , et al. TP53 mutants in the tower of babel of cancer progression. Hum Mutat. 2014;35(6):689–701.
   PubMed Web of Science ®Google Scholar
• Sabapathy K , Lane DP . Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15(1):13–30.
   PubMed Web of Science ®Google Scholar
• Monti P , Ciribilli Y , Jordan J , et al. Transcriptional functionality of germ line p53 mutants influences cancer phenotype. Clin Cancer Res. 2007;13(13):3789–3795.
   PubMed Web of Science ®Google Scholar
• Trbusek M , Smardova J , Malcikova J , et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. JCO. 2011;29(19):2703–2708. .
   PubMed Web of Science ®Google Scholar
• Gurtner A , Starace G , Norelli G , et al. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem. 2010;285(19):14160–14169.
   PubMed Web of Science ®Google Scholar
• Mraz M , Pospisilova S , Malinova K , et al. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma. 2009;50(3):506–509. .
   PubMed Web of Science ®Google Scholar
• Te Raa GD , Malčiková J , Mraz M , et al. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. Br J Haematol. 2014;167(4):565–569.
   PubMed Web of Science ®Google Scholar
• Navrkalova V , Sebejova L , Zemanova J , et al. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. Haematologica. 2013;98(7):1124–1131.
   PubMed Web of Science ®Google Scholar
• Cerna K , Oppelt J , Chochola V , et al. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia. 2019;33(2):403–414.
   PubMed Web of Science ®Google Scholar
• Best OG , Gardiner AC , Majid A , et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia. 2008;22(7):1456–1459.
   PubMed Web of Science ®Google Scholar
• Malcikova J on behalf of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network , Tausch E , Rossi D , et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation. Leukemia. 2018;32(5):1070–1080.
   PubMed Web of Science ®Google Scholar
• Campo E , Cymbalista F , Ghia P , et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956–1968.
   PubMed Web of Science ®Google Scholar
• Pavlova S , Smardova J , Tom N , et al. Detection and Functional Analysis of TP53 Mutations in CLL. Methods Mol Biol. 2019;1881:63–81.
   PubMedGoogle Scholar
• Zenz T , Krober A , Scherer K , et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322–3329.
   PubMed Web of Science ®Google Scholar
• Rossi D , Khiabanian H , Spina V , et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123(14):2139–2147.
   PubMed Web of Science ®Google Scholar
• Rossi D , Cerri M , Deambrogi C , et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15(3):995–1004.
   PubMed Web of Science ®Google Scholar
• Malcikova J , Stano-Kozubik K , Tichy B , et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 2015;29(4):877–885.
   PubMed Web of Science ®Google Scholar
• Cutrona G , Tripodo C , Matis S , et al. Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. Sci Transl Med. 2018;10:428.
   Web of Science ®Google Scholar
• Dicker F , Schnittger S , Haferlach T , et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood. 2006;108(9):3152–3160.
   PubMed Web of Science ®Google Scholar
• Rigolin GM , Cavallari M , Quaglia FM , et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood. 2017;129(26):3495–3498.
   PubMed Web of Science ®Google Scholar
• Baliakas P , Jeromin S , Iskas M , et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205–1216.
   PubMed Web of Science ®Google Scholar
• Rossi D , Spina V , Gaidano G . Biology and treatment of Richter syndrome. Blood. 2018;131(25):2761–2772.
   PubMed Web of Science ®Google Scholar
• Anderson MA , Tam C , Lew TE , et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017;129(25):3362–3370.
   PubMed Web of Science ®Google Scholar
• Filip D , Mraz M . The role of MYC in the transformation and aggressiveness of “indolent” B-cell malignancies. Leuk Lymphoma. 2020;61(3):510–524.
   PubMed Web of Science ®Google Scholar
• Zenz T , Eichhorst B , Busch R , et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473–4479.
   PubMed Web of Science ®Google Scholar
• Condoluci A , Terzi Di Bergamo L , Langerbeins P , et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859–1869. .
   PubMed Web of Science ®Google Scholar
• Best OG , Gardiner AC , Davis ZA , et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23(1):212–214.
   PubMed Web of Science ®Google Scholar
• Tam CS , Seymour JF . A predictive tool for early-stage CLL. Blood. 2020;135(21):1820–1821.
   PubMed Web of Science ®Google Scholar
• Mato AR , Barrientos JC , Ghosh N , et al. Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry. Clin Lymphoma Myeloma Leuk. 2020;20(3):174–183.e3.
   PubMed Web of Science ®Google Scholar
• Ravandi F , O’brien S . Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest. 2006;24(7):718–725.
   PubMed Web of Science ®Google Scholar
• Gauthier J , Hirayama AV , Purushe J , et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650–1660.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA , Kumar A , Hamadani M , et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines committee of the american society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2016;22(12):2117–2125.
   PubMed Web of Science ®Google Scholar